340 related articles for article (PubMed ID: 25335717)
1. [Efficacy of WT1 peptide-/MUC-1 peptide-pulsed dendritic cell therapy in 313 patients with a wide range of cancers].
Kato Y
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1280-2. PubMed ID: 25335717
[TBL] [Abstract][Full Text] [Related]
2. [WT1 Class I Peptide/WT1 Class II Peptide Pulsed Dendritic Cell Therapy Efficacy in 60 Patients with a Wide Range of Advanced Cancers].
Kato Y
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1252-1255. PubMed ID: 27760951
[TBL] [Abstract][Full Text] [Related]
3. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
[TBL] [Abstract][Full Text] [Related]
4. [WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers].
Kato Y
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2240-2. PubMed ID: 21224534
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
6. [Prediction of WT1/MUC1 peptide dendritic cell therapy responders by quantification of ex vivo induced mRNA in whole blood].
Kato Y; Mitsuhashi M
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1803-5. PubMed ID: 23267892
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.
Zhang W; Lu X; Cui P; Piao C; Xiao M; Liu X; Wang Y; Wu X; Liu J; Yang L
Cancer Immunol Immunother; 2019 Jan; 68(1):121-130. PubMed ID: 30306202
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.
Ohno S; Okuyama R; Aruga A; Sugiyama H; Yamamoto M
Anticancer Res; 2012 Jun; 32(6):2263-9. PubMed ID: 22641661
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer.
Kobayashi M; Sakabe T; Abe H; Tanii M; Takahashi H; Chiba A; Yanagida E; Shibamoto Y; Ogasawara M; Tsujitani S; Koido S; Nagai K; Shimodaira S; Okamoto M; Yonemitsu Y; Suzuki N; Nagaya M;
J Gastrointest Surg; 2013 Sep; 17(9):1609-17. PubMed ID: 23877328
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
12. [WT1-targeting cancer vaccine].
Sugiyama H
Nihon Rinsho; 2012 Dec; 70(12):2105-13. PubMed ID: 23259381
[TBL] [Abstract][Full Text] [Related]
13. [WT1 peptide cancer vaccine].
Sugiyama H
Nihon Rinsho; 2017 Feb; 75(2):263-269. PubMed ID: 30562862
[TBL] [Abstract][Full Text] [Related]
14. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.
Coosemans A; Wölfl M; Berneman ZN; Van Tendeloo V; Vergote I; Amant F; Van Gool SW
Anticancer Res; 2010 Sep; 30(9):3709-14. PubMed ID: 20944158
[TBL] [Abstract][Full Text] [Related]
15. Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells.
Yamaguchi Y; Ohta K; Kawabuchi Y; Ohshita A; Okita R; Okawaki M; Hironaka K; Matsuura K; Toge T
Anticancer Res; 2005; 25(3c):2407-15. PubMed ID: 16080467
[TBL] [Abstract][Full Text] [Related]
16. Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination.
Ohno S; Takano F; Ohta Y; Kyo S; Myojo S; Dohi S; Sugiyama H; Ohta T; Inoue M
Anticancer Res; 2011 Jul; 31(7):2447-52. PubMed ID: 21873158
[TBL] [Abstract][Full Text] [Related]
17. WT1 peptide vaccine for the treatment of cancer.
Oka Y; Tsuboi A; Oji Y; Kawase I; Sugiyama H
Curr Opin Immunol; 2008 Apr; 20(2):211-20. PubMed ID: 18502632
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell vaccination of patients with metastatic colorectal cancer.
Burgdorf SK
Dan Med Bull; 2010 Sep; 57(9):B4171. PubMed ID: 20816019
[TBL] [Abstract][Full Text] [Related]
19. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia.
Kitawaki T; Kadowaki N; Kondo T; Ishikawa T; Ichinohe T; Teramukai S; Fukushima M; Kasai Y; Maekawa T; Uchiyama T
Am J Hematol; 2008 Apr; 83(4):315-7. PubMed ID: 18081032
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.
Ueda Y; Itoh T; Nukaya I; Kawashima I; Okugawa K; Yano Y; Yamamoto Y; Naitoh K; Shimizu K; Imura K; Fuji N; Fujiwara H; Ochiai T; Itoi H; Sonoyama T; Hagiwara A; Takesako K; Yamagishi H
Int J Oncol; 2004 Apr; 24(4):909-17. PubMed ID: 15010829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
